Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors

US11535635B2 · kind B2 · utility

Assignee

• HiberCell, Inc. · US

Inventors

• Johan Lindström · Huddinge, SE
• Lars Boukharta Persson · Uppsala, SE
• Jenny Viklund · Kungshättan, SE
• Rickard Forsblom · Tullinge, SE
• Tobias Ginman · Tullinge, SE
• Edward A. Kesicki · Bothell, US
• Eugene Richard Hickey · Danbury, US
• Markus Dahlgren · Stratford, US
• Aleksey I. Gerasyuto · Flemington, US

Key dates

• Filing date: Dec 21, 2018
• Grant date: Dec 27, 2022
• Expiry date: Dec 21, 2038

Classification

• Technology area (CPC —): General

Abstract

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.